In Vitro and In Vivo Evaluation of Commercially Available Fibrin Gel as a Carrier of Alendronate for Bone Tissue Engineering

Figure 7

Hematoxylin and eosin-stained microscopic images of the margin of the defect site at 2, 4, and 8 weeks after implantation of fibrin gel or fibrin/ALN gel (containing 10⁻⁶M ALN). Newly formed bone at the periphery of the defect was observed in both the fibrin gel and fibrin/ALN groups from 2 weeks after implantation. Mature bone was more abundant in the fibrin/ALN group and newly formed bone tended to coalesce with the host bone. Hb, host bone; Nb, new bone. Scale bar: 250 μm.